**SPECIAL FEATURES**

**CCR Translations**

4419  
TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal  
Ramaswamy Govindan and Jason Weber  
See related article, p. 4647

4422  
"Companion Diagnostics": Has Their Time Come and Gone?  
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst  
See related article, p. 4488

**CCR New Strategies**

4425  
New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs  
Juliane M. Jürgensmeier, Joseph P. Eder, and Roy S. Herbst

**CCR Perspectives in Drug Approval**

4436  
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer  

**Molecular Pathways**

4442  
Molecular Pathways: Targeting ETS Gene Fusions in Cancer  
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

**CANCER THERAPY: CLINICAL**

4449  
Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)  

4459  
p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8⁺ T-cell Responses  
Nicola R. Hardwick, Mary Carroll, Teodora Kalcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D.L. Ellenhorn, Don J. Diamond, and Vincent Chung

4471  
Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients  
Jacques Medioni, Gail Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houillier, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartine, Reza Elaïdi, Celine Lerest, and Stephane Oudard

**PERSONALIZED MEDICINE AND IMAGING**

4478  
Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer  
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Christopher Stroh

4488  
Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit  
See related commentary, p. 4422
**CANCER THERAPY: PRECLINICAL**

4559 Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer

Zhe Zhang, Jiping Wang, Dongmei Ji, Chenchao Wang, Ruijiao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jun Li

4574 SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38⁺ Hematologic Malignancies

Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skalektsayia, Vicent S. Golkachcher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

**BIOLOGY OF HUMAN TUMORS**

4598 Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis

Zhaojun Liu, Jun Zhang, Yanhong Gao, Lirong Pei, Jing Zhou, Liankun Gu, Lianhai Zhang, Budong Zhu, Naoko Hattori, Jiafu Ji, Yasuhiro Yuasa, Wooko Kim, Toshikazu Ushijima, Huidong Shi, and Dajun Deng

4613 Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanché, Nicolas Girard, Jean Trédaniel, Laurent Guilleminault, Radv Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivière, Pascal Foucher, Bernard Duver, Maxime Vallée, Florence Le Calvez-Kelm, James McKay, Pascale Missy, Franck Morin, Gérard Zalcman, Magali Olivier, and Pierre-Jean Souquet for the BioCAST/IFCT-1002 investigators
Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer

Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpei Kumagai, Haruki Kume, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer

Sajni Josson, Murali Gururajan, Peizhen Hu, Chen Shao, Gina Chia-Yi Chu, Haiyen E. Zhao, Chunyan Liu, Kaiqin Lao, Chia-Lun Lu, Yi-Tsung Lu, Jake Lichterman, Srinivas Nandana, Quanlin Li, Andre Rogatko, Dror Berel, Edwin M. Posadas, Ladan Fazli, Dhruv Sareen, and Leland W.K. Chung

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gasco, Clara Mayo-de-Las-Casas, Maria Sanchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andres F. Cardona, Alain Vergnenegre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell

See related commentary, p. 4419

To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiwarshi, Chunbo Shao, Anke Bill, Jean Kim, Dong Xiao, Carol A. Bertrand, Raja S. Seethala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manoj Kumar A. Puthenveedu, and Umamaheswar Duvvuri

TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome

Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Wang, Linlin Ren, Huijun Zhao, Yinchao Wang, Yingxuan Chen, Jie Xie, Yongbing Xiang, Wenxin Qin, Weibiao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang

Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression

Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin

GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion

Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.
# Clinical Cancer Research

20 (17)

*Clin Cancer Res* 2014;20:4417-4729.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/20/17">http://clincancerres.aacrjournals.org/content/20/17</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>